Trial reportThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2010
Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation.
Trial report in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06112951 (The Use of Extracorporeal Photopheresis as Immunomodulatory Therapy of Subclinical Antibody-mediated Rejection After Lung Transplantation), which is not on this map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Use of Extracorporeal Photopheresis as Immunomodulatory Therapy of Subclinical Antibody-mediated Rejection After Lung Transplantation: a Prospective RCT
Who cites it
87 citing papers in PubMed, 232 citations in OpenAlex.
- The clinical impact of humoral immunity in pediatric renal transplantation.Journal of the American Society of Nephrology : JASN · 2013Trial
- Extracorporeal Photopheresis in Lung Transplantation: Present Applications and Emerging Research.Transplantation direct · 2025Article
- Article
- Efficacy of Intravenous Immunoglobulin in Eliminating De Novo Donor-Specific Antibodies After Lung Transplantation: Importance of Early Intervention.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Pushing the Survival Bar Higher: Two Decades of Innovation in Lung Transplantation.Journal of clinical medicine · 2024Review
- Pseudomonas aeruginosa infection correlates with high MFI donor-specific antibody development following lung transplantation with consequential graft loss and shortened CLAD-free survival.Respiratory research · 2024Article
- Preemptive Treatment of De Novo Donor Specific Anti-HLA Antibodies With IVIG Monotherapy after Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Immunopathology of lung transplantation: from infection to rejection and vice versa.Frontiers in immunology · 2024Review
- Impact of Transient and Persistent Donor-Specific Antibodies in Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Anti-CD20 Antibody and Calcineurin Inhibitor Combination Therapy Effectively Suppresses Antibody-Mediated Rejection in Murine Orthotopic Lung Transplantation.Life (Basel, Switzerland) · 2023Article
- Tocilizumab for antibody-mediated rejection treatment in lung transplantation.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2023Article
- Preemptive immune globulin therapy in sensitized lung transplant recipients.Transplant immunology · 2023Article
- Preemptive treatment of de novo donor-specific antibodies in lung transplant patients reduces subsequent risk of chronic lung allograft dysfunction or death.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023Article
- Antibody-Mediated Rejection: Diagnosis and Treatment.Clinics in chest medicine · 2023Review
- Management of donor-specific antibodies in lung transplantation.Frontiers in transplantation · 2023Review
- CD16American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023Article
- Immune processes in the pathogenesis of chronic lung allograft dysfunction: identifying the missing pieces of the puzzle.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Current perspective of immunomodulators for lung transplant.Indian journal of thoracic and cardiovascular surgery · 2022Review
- Extracellular Vesicles Mediate Immune Responses to Tissue-Associated Self-Antigens: Role in Solid Organ Transplantations.Frontiers in immunology · 2022Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundBecause the development of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) after lung transplantation has been associated with acute and chronic rejection, we implemented a clinical protocol to screen all transplant recipients for DSA and preemptively treat those who developed DSA with rituximab and intravenous immune globulin (IVIG), or IVIG alone.
methodsWe conducted a prospective observational study of this protocol and used the LABScreen Single Antigen assay to detect DSA after transplantation. We compared the incidence of acute rejection, lymphocytic bronchiolitis, and bronchiolitis obliterans syndrome (BOS) between those who developed DSA and those who did not using Cox proportional hazards models. We used the Kaplan-Meier method to compare freedom from BOS and survival between those who had persistent DSA and those who had successful depletion of DSA.
resultsAmong 116 recipients screened, DSA developed in 65 during the study period. Those who developed DSA and received antibody-directed therapy had a similar incidence of acute rejection, lymphocytic bronchiolitis, and BOS as those who did not develop DSA. Furthermore, recipients who had successful depletion of DSA had greater freedom from BOS and better survival than those who had persistent DSA. Finally, those treated for DSA had a similar incidence of infectious complications as those who did not develop DSA.
conclusionsThe development of DSA is surprisingly common after lung transplantation. Antibody-directed therapy may reduce the risk of rejection associated with DSA, but a randomized controlled trial is necessary to critically evaluate the efficacy of this treatment protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.